BillionToOne, Inc. vs CAREDX, INC., two Medical Diagnostics stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where BLLN and CDNA diverge most: on debt / equity, BLLN reads 0.17 and CDNA reads 0.00; on operating margin, BLLN reads 5.0% and CDNA reads 85.8%. The rest of the comparable metrics sit closer together. The bull and bear cases for each are in their full reports below.
| Metric | BLLN | CDNA |
|---|---|---|
| Price | $98.15 | $63.64 |
| Market cap | $5.3B | $3.3B |
| Sector | Medical Diagnostics | Medical Diagnostics |
| Stage | Growth | Growth |
| P/E | 172.2 | 30.7 |
| P/B | 9.96 | 7.74 |
| P/S | 14.53 | 7.19 |
| EV/EBITDA | 127.4 | 25.2 |
| Revenue growth | +88.5% | +34.3% |
| Gross margin | 70.5% | — |
| Operating margin | 5.0% | 85.8% |
| Net margin | 8.6% | 24.2% |
| Return on equity | 5.9% | 26.1% |
| Return on assets | 4.3% | 20.8% |
| Return on invested capital | 4.6% | 24.6% |
| FCF yield | 0.6% | 2.7% |
| Debt / equity | 0.17 | 0.00 |
| Current ratio | 11.69 | 4.58 |
| Altman Z (solvency) | 7.03 | 6.99 |
| Piotroski F (quality) | 6 / 9 | 5 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.